Starpharma Holdings Ltd and Nufarm Limited Sign Crop Protection Agreement
Published: Aug 07, 2012
“We are very pleased to be working with Nufarm in this way,” commented Dr Jackie Fairley, CEO Starpharma. “This agreement builds on previous collaboration between the companies and we are excited about the opportunity to work with Nufarm to develop innovative and improved products.”
“This collaboration with Starpharma reflects Nufarm’s renewed emphasis on technological innovation,” said Lachlan McKinnon, Nufarm Australia's General Manager. “We are seeking innovative ways to differentiate our products so that growers are offered a wider range of control options tailored to their particular needs.”
Starpharma’s Priostar® dendrimer technology has wide applicability in the agrochemical sector. Through its own internal research program Starpharma has previously established that potential benefits of dendrimer to agrochemical formulators and end-user growers include:
• More concentrated formulations to reduce transport costs;
• Reduction in solvent loading;
• Improved overall activity; and
• Increased adhesion, to reduce losses due to rain run-off, and the need for multiple applications.
The terms of the agreement were not disclosed due to commercial confidentiality restrictions.
About Nufarm Limited
Nufarm Limited is one of the world's leading crop protection companies. Nufarm produces products to help farmers protect their crops against damage caused by weeds, pests and disease.
With manufacturing and marketing operations based in Australia, New Zealand, Asia, Europe and the Americas, Nufarm employs more than 3,000 people, all of whom make a vital contribution to the company's reputation for quality products, innovation and first class marketing and technical support.
Group Sales for FY2011 exceeded $2billion.
Proudly based in Australia, Nufarm is listed on the Australian Stock Exchange (symbol NUF). Nufarm is the largest manufacturer of crop protection products in Australia.
About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and other uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery and agrochemicals with the Company developing a number of products internally and others via commercial partnerships. In addition, products for diagnostics and laboratory reagents are already on market through licence arrangements with partners including Siemens Healthcare and Merck KGaA.
Starpharma’s lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes.
Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.
In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Most recently Starpharma announced pre-clinical results in its Docetaxel (Taxotere®) program demonstrating significant improvements in that agent’s anticancer efficacy and the enhancement of solubility offering potential safety benefits as well. The company is also exploring dendrimer opportunities in agrochemicals in a series of industry partnerships as well as with internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®). Starpharma’s headquarters and research facilities are located in Melbourne, Australia
For Further Information:
Mob: +61 417 382 391
Mob: +61 423 139 163
Dr Jackie Fairley, Chief Executive Officer
+61 3 8532 2704
Ben Rogers, Company Secretary
Marketing Communications Manager
Phone: 03 9282 1578
Mobile: 0408 944 806